Coming soon: news from HIVR4P 2018

Gus Cairns
Published: 18 October 2018

The third HIV Research for Prevention conference (HIVR4P) in Madrid next week (21 to 25 October) will feature news from every aspect of HIV prevention. HIVR4P came from a merger between the HIV vaccine and HIV microbicides conferences, and the breadth of its coverage reflects this. 

Plenary sessions will cover the latest in progress towards an HIV vaccine, what vaccine science is telling us about the mechanisms of HIV transmission, novel developments of pre-exposure prophylaxis (PrEP) including implants and rings, and the use of broadly neutralising antibodies in HIV prevention.

But the focus will also be very much in implementation science. The PROUD trial’s Sheena McCormack will talk about designing PrEP trials for populations as yet unreached by it; US Chief HIV Scientist Anthony Fauci will talk about the programmes we need to put in place to end the HIV epidemic; and Spanish HIV activist Michael Meulbroek is part of a final plenary session on multiple prevention strategies, when he talks about the impact of introducing combination HIV prevention including PrEP at the Checkpoint clinic in Barcelona.

Expect news on the impact of PrEP programmes on HIV incidence in other cities too, on immune responses in previous and ongoing vaccine trials including the Uhambo trial underway in South Africa, on how PrEP may be processed differently within vaginal rather than rectal tissue, and on therapeutic vaccines and their possible part to play in an HIV cure.

First off on the Sunday morning there is also an advocates’ pre-conference session hosted by IRMA (International Rectal Microbicide Advocates) and AVAC and featuring an hour’s panel; and discussion on the state of PrEP in Europe, led by the organisation of that name (see

Conference reporting on

We’ll be reporting from HIVR4P 2018, publishing news at, and will send out one conference summary bulletin in English in the week following the conference. You can sign up here to receive the bulletin. (If you already subscribe to one of our regular news bulletins, you will automatically receive this conference bulletin.)

Please feel free to link to our news stories, bulletins and any other pages – in emails, newsletters and blogs or in other social media like Facebook and Twitter.

For more information on the conference, visit the official conference website and view the online conference programme.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.